



MANUFACTURING CHEMISTS ASSOCIATION

1825 CONNECTICUT AVENUE, N.W. WASHINGTON, D.C. 20009 (202) 483-6126

ALBERT C. CLARK
VICE PRESIDENT
TECHNICAL DIRECTOR

14, 19

CHEMICALS
RESEARCH

OCT 17 1977

October 13, 1977

Mr. H. R. Flammer
Manager, Business Area
Continental Oil Company
5 Greenway Plaza East
P. O. Box 2197, Suite 1918
Houston, Texas 77001

*Left note for
BKF (10/19/77)
indicating Conoco
support was estimated
in late Aug. to be \$25-30,000,
based on current support.*

SK	_____
CCR	_____
ALL	_____
DVP	_____
EL	_____
AL	_____
WRS	_____
LM	_____

Subject: Vinyl Chloride Research Program - Continuation
of Multi-Component Studies at the University of
Louisville

Dear Mr. Flammer:

The Technical Panel on Vinyl Chloride Research recommends continuation of the multi-component research program on "Research Techniques and Methods of Detection and Prevention of Carcinogenesis in Industrial Workers" at the School of Medicine, University of Louisville. This research has as its objectives the design of methods for early detection, prevention, diagnosis and treatment of those individuals exposed to potentially toxic chemicals with the aim of preventing any serious injury, pre-cancerous lesions, or the development of cancer either on a short or long-term basis. The program is designed to identify, at the earliest possible time, potentially harmful chemicals and to lead to a reduction in their exposure based on objective chemical data.

Simultaneously, research is being conducted at the University of Louisville on the problem of vinyl chloride toxicity and disease developed in animal models. Studies of these types are of key importance in testing the potentially more effective methods of detection and/or treatment.

Among the important phases of this overall program is the evaluation of immunocompetence systems of individuals with both short and long-term exposure to vinyl chloride and other chemicals. This evaluation is designed to aid in identifying

DTH 000013326

defective or reduced immune surveillance prior to the development of malignancy.

The cost of continuing this research through fiscal year 1977-1978 is as follows:

I. Clinical Immunology	\$ 50,046
II. Clinical Biochemistry - Enzymic Systems	36,300
III. Clinical Biochemistry - Biochemical Changes	17,700
IV. Clinical Pathology	7,735
V. Microbiology	27,560
VI. Chemistry	27,552
VII. Pathology	21,190
Indirect Costs	<u>59,765</u>
Subtotal	\$247,848
Supplemental Research Costs	24,785
Administrative	24,785
TOTAL	\$297,418

It is the view of Panel Members that if this overall program is to yield optimum results it is important that its continuity be preserved. Work under the 1976-1977 contract will terminate during the later part of this month or during the first two weeks of November. Members of the Technical Panel urge therefore that in the event that you wish this program to continue, that your commitment be returned by October 28, 1977.

Sincerely,



cc: Dr. Flynt Kennedy